St. Jude CEO: Medtronic's renal denervation miss doesn't dampen our spirits

January 13, 2014 by Arezu Sarvestani

St. Jude Medical president & CEO Dan Starks says that rival Medtronic's failed renal denervation study is no reason to stop pursuing the technology in treatment of hypertension.

St. Jude CEO: Medtronic's miss doesn't dampen our spirits

St. Jude Medical (NYSE:STJ) CEO Daniel Starks remains steadfast in his pursuit of renal denervation in treatment of hypertension, despite the high-profile clinical trial flop suffered just last week by rival medtech titan Medtronic (NYSE:MDT).

St. Jude will continue with its renal denervation initiatives and Starks still sees the technology as a potential winner, he told an audience today at the J.P. Morgan Healthcare conference in San Francisco.

Sign up to get our free newsletters delivered right to your inbox.

"I think we're just in the very early stages of figuring out how to best help patients with a renal denervation procedure, but there's nothing in [Medtronic's] announcement that dissuades us from continuing to pursue this," Starks said.